Table 1.
Summary table of the meta-analysis
| Study Cohort | Study region | No (M/F, n) | NO. of elevated PLT (%) | Age (ys) (median and range) | Clinical stage | AC/SCC | Cutoff | Outcome | Follow-up (months) (median and range) | Hazard ratios | Treatment (predominant) | Smoking history yes/no |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aoe (2004) | Japan | 482/129 | 98 (16.0) | 64 (24-89) | I-IV | 239/128 | 400 × 109/L | OS | NR | Reported | NR | NR |
| Du (2012) | China | 195/63 | 151 (58.5) | 53 (31-75) | IIIA-IV | 163/95 | 400 × 109/L | OS | 38 (3-86) | Reported | chemotherapy | NR |
| Yu (2012) | China | 388/122 | 61 (11.9) | 60 (37-82) | I-III | 232/253 | 300 × 109/L | OS | NR | Reported | Surgery | 354/156 |
| Liu (2013) | China | 615/268 | 138 (15.7) | 63 (18-89) | I-IV | 475/303 | 214.5 × 109/L | OS | NR | Reported | Surgery | NR |
| Maráz (2013) | Hungary | 293/105 | 86 (21.6) | NR | I-IV | 163/175 | 400 × 109/L | OS | 62 (1-103) | Reported | Surgery | 249/99 |
| Luo (2012) | USA | 56/54 | 37 (33.6) | (50-89) | I-IV | NR | 300 × 109/L | OS | NR | Reported | NR | 99/11 |
| Barcala (2010) | Spain | 35/446 | 103 (21.4) | 66 | I-IV | 94/188 | 381 × 109/L | OS | NR | Estimated | NR | 414/27 |
| Adžić (2011) | Serbia | 161/39 | 33 (16.5) | (42-78) | I-IV | 55/140 | 420 × 109/L | OS | 25 (1-84) | Estimated | Surgery | NR |
| Kim (2014) | Korea | 149/50 | 15 (7.5) | 65 (20-84) | I-III | 107/75 | 400 × 109/L | OS | 65 (0.7-102) | Reported | Surgery | 136/63 |
| Ji (2014) | China | 168/66 | 20 (8.5) | NR | I | 121/100 | 300 × 109/L | OS | NR | Reported | Surgery | 154/80 |
| Kim (2014) | Korea | 558/296 | 59 (6.9) | 66.3 (65.5-67) | IIIA-IV | 203/384 | 450 × 109/L | OS | NR | Reported | MT | NR |
| Holgersson (2012) | Sweden | 755/391 | 293 (25.5) | NR | I-IV | 321/652 | 350 × 109/L | OS | NR | Reported | MT | 1088/58 |
AC: adenocarcinoma; SCC: squamous carcinoma; OS: overall survival; NR: not reported; ys: years; MT: multiple therapy.